glp-1 in pregnancy Preconception receptor agonist use may reduce risks GLP-1 Weight Loss Meds &

Davies MJ, Aroda VR, Collins BS et al (2022) Management of hyperglycemia in type 2 diabetes, 2022

In a mixed-treatment comparison meta-analysis of randomized controlled trials of GLP-1 receptor agonists (exenatide BID and QW and liraglutide) in overweight or obese patients with type 2 diabetes, mean reductions in body weight were greater than with placebo for exenatide 10 g BID (1.4 kg), exenatide QW (1.6 kg), and liraglutide 1.8 mg (1.5 kg), with no significant differences among these three treatments (24)

Recent research backs this up, showing higher gastroparesis rates in people who use semaglutide compared to other weight loss methods

They should be reading that paperwork. Anyone who wants to try a non-FDA-approved treatment should verify that the provider can handle all potential complications

Practical Takeaways for Patients GLP-1 medications arent just for weight loss they improve metabolic and cardiovascular health